Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349.HK)
HKD 2.57
(5.76%)
HKD 2.57
(5.76%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 108.62 Million CNY | -21.28% |
| 2022 | 137.99 Million CNY | -35.3% |
| 2021 | 213.29 Million CNY | 29.53% |
| 2020 | 164.66 Million CNY | -27.58% |
| 2019 | 227.35 Million CNY | 50.59% |
| 2018 | 150.98 Million CNY | 100.54% |
| 2017 | 75.28 Million CNY | -45.72% |
| 2016 | 138.7 Million CNY | 8.6% |
| 2015 | 127.72 Million CNY | 8.0% |
| 2014 | 118.25 Million CNY | 35.59% |
| 2013 | 87.21 Million CNY | 64.07% |
| 2012 | 53.15 Million CNY | 72.45% |
| 2011 | 30.82 Million CNY | 737.44% |
| 2010 | 3.68 Million CNY | 150.29% |
| 2009 | -7.32 Million CNY | 68.72% |
| 2008 | -23.4 Million CNY | 20.81% |
| 2007 | -29.55 Million CNY | -34.14% |
| 2006 | -22.03 Million CNY | 27.43% |
| 2005 | -30.35 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 68.12 Million CNY | 2802.18% |
| 2024 Q1 | 2.34 Million CNY | -87.47% |
| 2023 Q1 | 8.78 Million CNY | -91.31% |
| 2023 Q2 | 59.65 Million CNY | 578.84% |
| 2023 FY | 108.62 Million CNY | -21.28% |
| 2023 Q3 | 21.45 Million CNY | -64.03% |
| 2023 Q4 | 18.73 Million CNY | -12.67% |
| 2022 Q2 | -40.9 Million CNY | -930.31% |
| 2022 Q4 | 101.17 Million CNY | 38.98% |
| 2022 FY | 137.99 Million CNY | -35.3% |
| 2022 Q3 | 72.79 Million CNY | 277.99% |
| 2022 Q1 | 4.92 Million CNY | -94.8% |
| 2021 FY | 213.29 Million CNY | 29.53% |
| 2021 Q1 | 5.11 Million CNY | -93.59% |
| 2021 Q2 | 60.36 Million CNY | 1079.68% |
| 2021 Q3 | 53.12 Million CNY | -11.99% |
| 2021 Q4 | 94.68 Million CNY | 78.21% |
| 2020 FY | 164.66 Million CNY | -27.58% |
| 2020 Q3 | 55.76 Million CNY | 17.74% |
| 2020 Q2 | 47.36 Million CNY | 357.66% |
| 2020 Q1 | -18.38 Million CNY | -117.36% |
| 2020 Q4 | 79.81 Million CNY | 43.12% |
| 2019 Q2 | 84.72 Million CNY | 1628.25% |
| 2019 Q1 | 4.9 Million CNY | -83.58% |
| 2019 Q4 | 105.88 Million CNY | 255.9% |
| 2019 FY | 227.35 Million CNY | 50.59% |
| 2019 Q3 | 29.75 Million CNY | -64.89% |
| 2018 Q4 | 29.86 Million CNY | 0.0% |
| 2018 FY | 150.98 Million CNY | 100.54% |
| 2018 Q2 | 26.2 Million CNY | 0.0% |
| 2018 Q3 | 29.86 Million CNY | 13.95% |
| 2018 Q1 | 26.2 Million CNY | 103.8% |
| 2017 Q3 | 12.85 Million CNY | -48.13% |
| 2017 Q4 | 12.85 Million CNY | 0.0% |
| 2017 Q2 | 24.78 Million CNY | 0.0% |
| 2017 Q1 | 24.78 Million CNY | -46.57% |
| 2017 FY | 75.28 Million CNY | -45.72% |
| 2016 Q3 | 46.38 Million CNY | 101.96% |
| 2016 Q2 | 22.96 Million CNY | 0.0% |
| 2016 Q1 | 22.96 Million CNY | -47.84% |
| 2016 FY | 138.7 Million CNY | 8.6% |
| 2016 Q4 | 46.38 Million CNY | 0.0% |
| 2015 FY | 127.72 Million CNY | 8.0% |
| 2015 Q4 | 44.03 Million CNY | 0.0% |
| 2015 Q2 | 19.83 Million CNY | 0.0% |
| 2015 Q3 | 44.03 Million CNY | 122.04% |
| 2015 Q1 | 19.83 Million CNY | -51.61% |
| 2014 Q3 | 40.98 Million CNY | 125.82% |
| 2014 Q4 | 40.98 Million CNY | 0.0% |
| 2014 FY | 118.25 Million CNY | 35.59% |
| 2014 Q1 | 18.14 Million CNY | -45.46% |
| 2014 Q2 | 18.14 Million CNY | 0.0% |
| 2013 Q2 | 20.36 Million CNY | 169.88% |
| 2013 Q4 | 33.27 Million CNY | 27.78% |
| 2013 FY | 87.21 Million CNY | 64.07% |
| 2013 Q1 | 7.54 Million CNY | -65.5% |
| 2013 Q3 | 26.04 Million CNY | 27.9% |
| 2012 FY | 53.15 Million CNY | 72.45% |
| 2012 Q4 | 21.86 Million CNY | 44.97% |
| 2012 Q3 | 15.08 Million CNY | 25.15% |
| 2012 Q2 | 12.05 Million CNY | 190.39% |
| 2012 Q1 | 4.15 Million CNY | -83.18% |
| 2011 Q3 | 2.78 Million CNY | -38.24% |
| 2011 FY | 30.82 Million CNY | 737.44% |
| 2011 Q1 | -1.16 Million CNY | -121.2% |
| 2011 Q2 | 4.51 Million CNY | 488.31% |
| 2011 Q4 | 24.68 Million CNY | 785.05% |
| 2010 FY | 3.68 Million CNY | 150.29% |
| 2010 Q4 | 5.48 Million CNY | 1006.05% |
| 2010 Q3 | 496 Thousand CNY | -51.32% |
| 2010 Q2 | 1.01 Million CNY | 130.69% |
| 2010 Q1 | -3.32 Million CNY | 0.0% |
| 2009 Q2 | -2.77 Million CNY | 0.0% |
| 2009 FY | -7.32 Million CNY | 68.72% |
| 2008 FY | -23.4 Million CNY | 20.81% |
| 2007 FY | -29.55 Million CNY | -34.14% |
| 2006 FY | -22.03 Million CNY | 27.43% |
| 2005 FY | -30.35 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 105.03 Million HKD | -3.416% |
| Grand Pharmaceutical Group Limited | 1.87 Billion HKD | 94.222% |
| Extrawell Pharmaceutical Holdings Limited | -162.94 Million HKD | 166.663% |
| Wai Yuen Tong Medicine Holdings Limited | -15.35 Million HKD | 807.394% |
| Qianhai Health Holdings Limited | -52.7 Million HKD | 306.104% |
| Lee's Pharmaceutical Holdings Limited | 16.69 Million HKD | -550.541% |
| Essex Bio-Technology Limited | 275.25 Million HKD | 60.536% |
| Tongfang Kontafarma Holdings Limited | -28.84 Million HKD | 476.616% |
| PuraPharm Corporation Limited | -106.08 Million HKD | 202.4% |
| SSY Group Limited | 1.31 Billion HKD | 91.762% |
| JBM (Healthcare) Limited | 130.46 Million HKD | 16.737% |
| Jacobson Pharma Corporation Limited | 266.96 Million HKD | 59.311% |
| China Resources Pharmaceutical Group Limited | 3.85 Billion HKD | 97.182% |